Recent News

• 11.05.2026 - Lucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive Year
• 11.04.2026 - Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
• 11.03.2026 - Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard® Study
• 10.29.2026 - Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026
• 10.22.2026 - Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing
• 09.22.2026 - Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways
• 08.13.2026 - Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results
• 08.05.2026 - Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test
• 08.04.2026 - Lucid Diagnostics to Participate in Upcoming Investor Conferences
• 07.30.2026 - Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026

Recent Filings

• 10.22.2026 - 8-K Current report
• 10.16.2026 - 8-K Current report
• 09.22.2026 - 8-K Current report
• 09.22.2026 - EX-99.1 EX-99.1
• 08.13.2026 - 8-K Current report
• 08.13.2026 - EX-99.1 EX-99.1
• 08.12.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 06.24.2026 - 8-K Current report
• 05.21.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.14.2026 - EX-99.1 EX-99.1